
Tariff hits to generic drugs could 'blow back on everybody' without supply chain resilience, says USP chief
While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily toward branded drugmakers, generic medicines and the companies that manufacture them will be uniquely vulnerable in the event of a …